Upstream Bio, Inc. - COMMON STOCK (UPB)

CUSIP: 91678A107

Q2 2025 13F Holders as of 30 Jun 2025

Holder snapshot 6 signals
Share change
+2,883,110
SEC-reported price per share
$10.98
Indexed holders
82
Value change
+$32,738,813
Number of buys
53
Number of sells
22
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
54,984,855

Security key

91678A107

Report period

Q2 2025

Indexed institutions

82

Top holders

10

Ownership snapshot

Top reported holders of UPB - Upstream Bio, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
0/15
Latest evidence
31 Mar 2025
13F 3/4/5 Highest disclosed value: $34,844,765 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC has the largest disclosed position value at $34.84M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.
Disclosed position value Top 5
ORBIMED ADVISORS LLC $34.84M
Decheng Capital LLC $20.11M
TCG Crossover Management, LLC $17.15M
Enavate Sciences GP, LLC $15.05M
Deep Track Capital, LP $14.07M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ORBIMED ADVISORS LLC
13F 3/4/5
Company · Director, 10%+ Owner
—
denominator unverified
$34,844,765
5,693,589 shares
— 31 Mar 2025
AI Upstream LLC
3/4/5
10%+ Owner
—
denominator unverified
—
5,494,410 shares
— 15 Oct 2024
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
3/4/5
10%+ Owner
—
denominator unverified
—
894,733 shares
— 15 Oct 2024
Decheng Capital LLC
13F
Company
13F
—
denominator unverified
$20,105,993
3,285,293 shares
— 31 Mar 2025
TCG Crossover Management, LLC
13F
Company
13F
—
denominator unverified
$17,146,790
2,801,763 shares
— 31 Mar 2025
Enavate Sciences GP, LLC
13F
Company
13F
—
denominator unverified
$15,053,382
2,459,703 shares
— 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
82
Shares
48,353,677
Indexed holders
82
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 indexed holders
76
Q2 2025 indexed holders
82
Indexed holder difference
6
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .